![](/wp-content/uploads/2018/10/sJFbRszQkiovfwxfUZKQ.png)
$599
Tandem’s t:slim X2 pump approved with Basal-IQ; Medtronic 670G approved for ages 7-13
Tandem announced FDA approval of its t:slim X2 insulin pump with Basal-IQ technology which utilizes a predictive low-glucose suspend (PLGS) feature, curiously with Dexcom G6 rather than G5 as previously communicated. Additionally, FDA has expanded the approval of the Medtronic MiniMed 670G to include children aged 7 to 13 with T1DM.